Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria

Area of Science:

• Hematology
• Pharmacology

Background:

• Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder with hemolysis, thrombosis, and bone marrow failure.
• Extravascular hemolysis is a key manifestation of PNH.

Purpose of the Study:

• To review the clinical efficacy and safety of danicopan for treating adults with PNH.
• To examine danicopan's role in managing extravascular hemolysis in PNH.

Main Methods:

• Systematic literature search of PubMed, Web of Science, Springer, Elsevier, and Wiley up to May 6, 2024.
• Review of clinical trial data, including the pivotal Phase 3 ALPHA trial.

Main Results:

• Danicopan targets the alternative complement pathway, inhibiting C3 fragment-mediated extravascular hemolysis.
• In the ALPHA trial, danicopan significantly increased hemoglobin levels (p < 0.0001), with 60% of patients achieving ≥2 g/dL increase versus 0% in placebo.
• Common adverse events included headache and upper respiratory tract infection.

Conclusions:

• Danicopan demonstrates significant efficacy in increasing hemoglobin levels for PNH patients with extravascular hemolysis.
• The drug is administered orally, with dosage adjustments possible, and requires vaccination against encapsulated bacteria prior to use.